Persimmune, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://persimmune.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)
Phase 1
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- PersImmune, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT03258359
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
Collection of Samples From Patients With MDS
- Conditions
- Myelodysplastic Syndromes(MDS)
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- PersImmune, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT03072498
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
Samples From Leukemia Patients and Their Donors to Identify Specific Antigens
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- PersImmune, Inc
- Target Recruit Count
- 50
- Registration Number
- NCT02667093
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
News
No news found